Pharma firms stash profits in Europe's tax havens

Pharma profits, R&D, and clinical risk

• Commenters note that pharma’s cumulative profits exceed reported R&D, while firms justify high prices by citing innovation costs.
• Several point out that most candidate drugs fail in clinical trials (especially in oncology), so hundreds of millions per failed drug are “lost” but still part of R&D.
• Some argue failures still generate knowledge; others stress shareholders only care about financial returns, not scientific learning.

Proposals: nationalization and public generics

• Repeated suggestions: governments should run drug manufacturers for off‑patent medicines, selling generics at cost and preventing single‑supplier gouging cases.
• Counterarguments: governments may run such entities inefficiently, and political capture could distort which drugs are produced and for whom.
• A “good enough” non‑profit, non‑optimized public producer is seen by some as an acceptable inefficiency.

Patents, pricing, and value of life

• Patents are framed as monopolies that block efficient allocation and testing of cheap off‑label uses.
• Debate over whether systems should prioritize the most effective drugs or cheaper options for budget reasons.
• Some point to explicit “value of a life” or QALY thresholds used by health agencies as evidence that prices on life are already set.

Tax havens, transfer pricing, and global rules

• Many emphasize these strategies are standard across multinationals, not unique to pharma.
• Techniques like transfer pricing and complex shell company chains (e.g., Dutch/Irish structures, Swiss/Luxembourg, Delaware, Zug) are discussed as legal but ethically dubious.
• Global minimum corporate tax efforts (OECD) are mentioned as a partial fix; enforcement and loopholes remain unclear.

Corporate vs individual taxation

• Some propose eliminating corporate tax and taxing shareholders (capital gains/dividends) instead.
• Others object that this rewards tax avoidance and that corporate tax, even if small in aggregate, still matters.
• There is disagreement over whether corporate expenses on perks (jets, arenas, hospitality) meaningfully constrain this model.

US tax burden debate

• One side claims taxes (especially in the US) are excessive and mostly wasted, with programs rarely ended.
• Others counter that effective tax rates are low by post‑WWII standards; another group replies that “historic lows” ignore pre‑1913 or pre‑New Deal baselines.
• Data on tax receipts as % of GDP is interpreted differently: some see stability since the 1940s, others see large absolute growth.

Global brain drain and EU inequities

• Commenters describe how free education in Southern/Eastern Europe trains engineers and doctors who then migrate to higher‑pay countries (UK, Northern Europe, US, Australia).
• This is viewed as a structural disadvantage for “periphery” countries, exacerbating inequality within Europe.

Investment perspective on Big Pharma

• Some compare big pharma stock returns to the S&P 500 and note that most large firms have underperformed broad indices or even short‑term government bonds.
• One blockbuster exception (a major weight‑loss drug firm) is acknowledged, but the consensus is that, for diversified investors, these tax maneuvers have not translated into outsized returns.